The invention relates to new thioridazine analogue compounds as a treatment for acute myeloid leukemia. In particular, the compounds show high cytotoxic activity on pediatric acute myeloid leukemia (AML) cells harboring a specific genetic rearrangement.
The invention relates to new thioridazine analogue compounds as a treatment for acute myeloid leukemia. In particular, the compounds show high cytotoxic activity on pediatric acute myeloid leukemia (AML) cells harboring a specific genetic rearrangement. The compounds have been designed to reduce central nervous system (CNS) side effects for pediatric applications. Without being bound to any theory, the inventors deem that a compound triggers a rise in intracellular Ca2+ with a novel cell death mechanism never exploited in pediatric AML. The molecule is a candidate as a new drug to be introduced in combined therapy for the treatment of pediatric acute myeloid leukemia with a specific genetic rearrangement. The invention belongs to the field of research to improve the treatment of these tumors which is still based on cytotoxic chemotherapy neither specific nor selective against tumor cells only.
Applications
Use as a medicament in the treatment of AML and especially a pediatric AML harboring a specific rearrangement.
Unismart - University of Padua Foundation
Create your free account to connect with Unismart - University of Padua Foundation and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Unismart - University of Padua Foundation
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
